A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this SLE study is to evaluate the efficacy, safety and tolerability of two
different doses of LY2127399 administered in addition to standard of care therapy in
participants with active SLE.